These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12394694)

  • 1. Editorial: Lessons learned from prostate biopsies.
    McCullough DL
    J Urol; 2002 Nov; 168(5):2000. PubMed ID: 12394694
    [No Abstract]   [Full Text] [Related]  

  • 2. [PSA 2010--the beginning of a new era in early detection of prostate cancer].
    Börgermann C; Sieverding M; Fornara P; Graefen M; Hammerer P; Semjonow A; Schröder F; Rübben H
    Urologe A; 2006 Sep; 45 Suppl 4():127-33. PubMed ID: 16941115
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial comment.
    Schilling D; Stenzl A
    J Urol; 2010 Feb; 183(2):527-8; discussion 528. PubMed ID: 20006885
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. I. PSA, PSA density, and predicted PSA].
    Rodríguez Rodríguez R; Mayayo Dehesa T; Galbis Sanjuan F; Jiménez Cidre M; Burgos Revilla FJ; Allona Almagro A; Gomez dos Santos V
    Arch Esp Urol; 1997 May; 50(4):333-8. PubMed ID: 9313041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prostate biopsy - an unending story].
    Mikuz G
    Pathologe; 2012 Mar; 33(2):99-102. PubMed ID: 22399196
    [No Abstract]   [Full Text] [Related]  

  • 6. The value of prostatic specific antigen density in the early diagnosis of prostate cancer.
    Deliveliotis Ch; Louras G; Kyriazis P; Gyftopoulos A; Louka L; Alargof E
    Int Urol Nephrol; 1998; 30(3):305-10. PubMed ID: 9696337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Billis et al.: Does the type of prostatic atrophy influence the association of extent of atrophy in needle biopsies and serum prostate-specific antigen levels? (Urology 2009;74:1111-1115).
    Papatsoris A; Albanis S; Deliveliotis C
    Urology; 2010 May; 75(5):1239; author reply 1240. PubMed ID: 20451754
    [No Abstract]   [Full Text] [Related]  

  • 8. The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL.
    Ng CF; Chiu PK; Lam NY; Lam HC; Lee KW; Hou SS
    Int Urol Nephrol; 2014 Apr; 46(4):711-7. PubMed ID: 24136184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosing prostate cancer: getting to the core question.
    Hernandez DJ
    J Urol; 2013 Jul; 190(1):11-2. PubMed ID: 23608039
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
    Partin AW; Walsh PC
    J Urol; 1994 Jul; 152(1):172-3. PubMed ID: 7515450
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial comment on: Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?
    Stanislaus P; Seitz M
    Eur Urol; 2009 Apr; 55(4):909-10. PubMed ID: 18485577
    [No Abstract]   [Full Text] [Related]  

  • 12. Intensifying the saturation biopsy technique for detecting prostate cancer after previous negative biopsies: a step in the wrong direction.
    Bott S; Langley S; Hindley R; Montgomery B
    BJU Int; 2009 Mar; 103(5):701. PubMed ID: 19226428
    [No Abstract]   [Full Text] [Related]  

  • 13. [How to use PSA in 2009].
    Ponholzer A; Stoiber F; Loidl W; Rauchenwald M; Schramek P; Madersbacher S
    Wien Med Wochenschr; 2009; 159(21-22):515-20. PubMed ID: 19997836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of free prostate-specific antigen measurement in prostate-specific antigen screening for prostate cancer.
    Johnson L
    Clin Prostate Cancer; 2002 Dec; 1(3):142-4. PubMed ID: 15046688
    [No Abstract]   [Full Text] [Related]  

  • 15. Comments on the article "Biomarkers for prostate cancer" by Eric Schiffer.
    Marshall S
    World J Urol; 2009 Aug; 27(4):577-8. PubMed ID: 19543735
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictive value of the international prostate symptom score for positive prostate needle biopsy in the low-intermediate prostate-specific antigen range.
    Kefi A; Irer B; Ozdemir I; Tuna B; Goktay Y; Yorukoğlu K; Esen A
    Urol Int; 2005; 75(3):222-6. PubMed ID: 16215309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. II. Rectal palpation, PSA, and transrectal echography].
    Rodríguez Rodríguez R; Mayayo Dehesa T; Galbis Sanjuan F; Jiménez Cidre M; Burgos Revilla FJ; Gómez dos Santos V; García González R
    Arch Esp Urol; 1997 May; 50(4):339-45. PubMed ID: 9313042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Lynch MJ
    J Urol; 2005 Sep; 174(3):1155; author reply 1155-6. PubMed ID: 16094096
    [No Abstract]   [Full Text] [Related]  

  • 19. The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.
    Thompson IM; Tangen CM; Ankerst DP; Chi C; Lucia MS; Goodman P; Parnes H; Coltman CA
    J Urol; 2008 Aug; 180(2):544-7. PubMed ID: 18550097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate specific antigen density: a method for differentiating prostate carcinoma from benign prostatic hypertrophy demonstrates ethnic variation.
    Martin AA; Clejan S
    J La State Med Soc; 1994 Apr; 146(4):163-71. PubMed ID: 7516401
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.